US 12,187,717 B2
Compound and use thereof in treating autoimmune diseases
Su Kil Seo, Busan (KR); Eun Hye Yoon, Busan (KR); Soung Min Lee, Busan (KR); Hae Jeong Won, Busan (KR); Won Hee Jang, Busan (KR); and Chae Eun Kim, Busan (KR)
Assigned to PARENCHYMA BIOTECH INC., Busan (KR)
Filed by PARENCHYMA BIOTECH INC., Busan (KR)
Filed on Aug. 30, 2023, as Appl. No. 18/239,842.
Application 18/239,842 is a continuation of application No. 18/138,817, filed on Apr. 25, 2023, granted, now 11,807,637.
Claims priority of application No. 10-2022-0075726 (KR), filed on Jun. 21, 2022; and application No. 10-2023-0018717 (KR), filed on Feb. 13, 2023.
Prior Publication US 2023/0406848 A1, Dec. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/428 (2006.01); A61K 31/4535 (2006.01); A61P 1/00 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01)
CPC C07D 417/12 (2013.01) [A61P 1/00 (2018.01); C07D 417/14 (2013.01)] 8 Claims
 
1. A method for treatment of autoimmune disease, the method comprising administering a pharmaceutical composition to a subject in need thereof,
wherein the pharmaceutical composition comprises a compound represented by Formula 1 below, a stereoisomer thereof or a pharmaceutically acceptable salt thereof,
wherein the autoimmune disease is any one selected from the group consisting of atopy, rheumatoid arthritis, systemic lupus erythematous and type 1 diabetes:

OG Complex Work Unit Chemistry
wherein, A is hydrogen, halogen, a hydroxyl group, a C1-C3 alkyl group, a C2-C3 alkenyl group, a C2-C3 alkynyl group, a C1-C3 alkoxy group, dimethylamine, —NO2, —CN, —COOR2 or —S(═O)2R2,
B is hydrogen, a C1-C3 alkyl group, a phenyl group, an acetyl group, —CH2C(═O)OR2, —C(═O)OR2 or —S(═O)2R2,
R1 is a substituted or unsubstituted 5-7 membered heterocyclic ring or —NH2, and
R2 is a C1-C3 alkyl group.